Samjin Pharm (005500) - Net Assets
Based on the latest financial reports, Samjin Pharm (005500) has net assets worth ₩264.51 Billion KRW (≈ $179.25 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩449.14 Billion ≈ $304.37 Million USD) and total liabilities (₩184.63 Billion ≈ $125.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Samjin Pharm (005500) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩264.51 Billion |
| % of Total Assets | 58.89% |
| Annual Growth Rate | 7.93% |
| 5-Year Change | 22.58% |
| 10-Year Change | 76.72% |
| Growth Volatility | 7.7 |
Samjin Pharm - Net Assets Trend (2013–2024)
This chart illustrates how Samjin Pharm's net assets have evolved over time, based on quarterly financial data. Also explore Samjin Pharm assets under control for the complete picture of this company's asset base.
Annual Net Assets for Samjin Pharm (2013–2024)
The table below shows the annual net assets of Samjin Pharm from 2013 to 2024. For live valuation and market cap data, see market value of Samjin Pharm.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩261.66 Billion ≈ $177.32 Million |
-1.40% |
| 2023-12-31 | ₩265.36 Billion ≈ $179.83 Million |
-3.81% |
| 2022-12-31 | ₩275.86 Billion ≈ $186.95 Million |
+17.81% |
| 2021-12-31 | ₩234.17 Billion ≈ $158.69 Million |
+9.70% |
| 2020-12-31 | ₩213.46 Billion ≈ $144.66 Million |
+8.09% |
| 2019-12-31 | ₩197.47 Billion ≈ $133.83 Million |
-3.82% |
| 2018-12-31 | ₩205.32 Billion ≈ $139.14 Million |
+6.13% |
| 2017-12-31 | ₩193.47 Billion ≈ $131.11 Million |
+14.01% |
| 2016-12-31 | ₩169.69 Billion ≈ $115.00 Million |
+14.61% |
| 2015-12-31 | ₩148.06 Billion ≈ $100.34 Million |
+17.47% |
| 2014-12-31 | ₩126.04 Billion ≈ $85.42 Million |
+11.56% |
| 2013-12-31 | ₩112.98 Billion ≈ $76.57 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Samjin Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 205.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩257.79 Billion | 98.52% |
| Other Components | ₩3.86 Billion | 1.48% |
| Total Equity | ₩261.66 Billion | 100.00% |
Samjin Pharm Competitors by Market Cap
The table below lists competitors of Samjin Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BioInvent International AB
ST:BINV
|
$155.44 Million |
|
Paragon Globe Bhd
KLSE:3611
|
$155.59 Million |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
$155.60 Million |
|
Habco Trans Maritima
JK:HATM
|
$155.64 Million |
|
MKH Oil Palm (East Kalimantan) Berhad
KLSE:5319
|
$155.38 Million |
|
Train Alliance Sweden AB Series B
ST:TRAIN-B
|
$155.35 Million |
|
Gobarto S.A.
WAR:GOB
|
$155.32 Million |
|
Shieh Yih Machinery Industry Co Ltd
TWO:4533
|
$155.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Samjin Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 265,364,997,000 to 261,655,068,260, a change of -3,709,928,740 (-1.4%).
- Net income of 39,232,983,400 contributed positively to equity growth.
- Dividend payments of 10,219,855,000 reduced retained earnings.
- Share repurchases of 9,984,980,100 reduced equity.
- Other factors decreased equity by 22,738,077,040.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩39.23 Billion | +14.99% |
| Dividends Paid | ₩10.22 Billion | -3.91% |
| Share Repurchases | ₩9.98 Billion | -3.82% |
| Other Changes | ₩-22.74 Billion | -8.69% |
| Total Change | ₩- | -1.40% |
Book Value vs Market Value Analysis
This analysis compares Samjin Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.19x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩15725.44 | ₩18710.00 | x |
| 2018-12-31 | ₩16688.83 | ₩18710.00 | x |
| 2019-12-31 | ₩16051.13 | ₩18710.00 | x |
| 2020-12-31 | ₩17350.19 | ₩18710.00 | x |
| 2021-12-31 | ₩19033.68 | ₩18710.00 | x |
| 2022-12-31 | ₩20810.66 | ₩18710.00 | x |
| 2023-12-31 | ₩20772.27 | ₩18710.00 | x |
| 2024-12-31 | ₩20886.66 | ₩18710.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Samjin Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.99%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.72%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.62x
- Recent ROE (14.99%) is above the historical average (12.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 6.97% | 4.10% | 0.94x | 1.81x | ₩-3.42 Billion |
| 2014 | 16.44% | 10.29% | 0.96x | 1.66x | ₩8.11 Billion |
| 2015 | 18.26% | 12.49% | 0.98x | 1.49x | ₩12.24 Billion |
| 2016 | 17.78% | 12.61% | 1.05x | 1.34x | ₩13.20 Billion |
| 2017 | 18.50% | 14.59% | 1.01x | 1.25x | ₩16.45 Billion |
| 2018 | 12.43% | 9.82% | 1.04x | 1.22x | ₩4.99 Billion |
| 2019 | 6.02% | 4.91% | 0.99x | 1.24x | ₩-7.87 Billion |
| 2020 | 13.06% | 11.86% | 0.87x | 1.26x | ₩6.53 Billion |
| 2021 | 12.13% | 11.36% | 0.75x | 1.42x | ₩4.99 Billion |
| 2022 | 7.95% | 7.99% | 0.67x | 1.48x | ₩-5.64 Billion |
| 2023 | 7.13% | 6.47% | 0.70x | 1.58x | ₩-7.63 Billion |
| 2024 | 14.99% | 12.72% | 0.73x | 1.62x | ₩13.07 Billion |
Industry Comparison
This section compares Samjin Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Samjin Pharm (005500) | ₩264.51 Billion | 6.97% | 0.70x | $155.42 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more